ARTELO BIOSCIENCES, INC.
Business
Artelo Biosciences is a clinical-stage biopharmaceutical company developing therapeutics that target lipid-signaling modulation pathways, including the endocannabinoid system. The company's pipeline includes ART27.13 (a dual CB1/CB2 agonist in Phase 1b/2a for cancer-related anorexia), ART26.12 (a FABP5 inhibitor in Phase 1 for chemotherapy-induced peripheral neuropathy and other indications), and ART12.11 (a proprietary CBD cocrystal in preclinical development for anxiety disorders and other conditions). Artelo operates globally through clinical research organizations and research institutions, with operations based in San Diego, California.
Summary from 10-K filed 2026-02-24
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| General and administrative | 6 | 4 | 4 | 6 | 6 | |
| Research and development | 5 | 6 | 6 | 4 | 4 | |
| Total Operating Expenses | 11 | 10 | 10 | 10 | 9 | |
| Loss from Operations | −11 | −10 | −10 | −10 | −9 | |
| Gain on investment | 22,000 | 0 | — | — | — | |
| Interest expense | −194,000 | 0 | 0 | −5,000 | — | |
| Interest expense - related party | −83,000 | 0 | — | — | — | |
| Loss on extinguishment of debt | −825,000 | 0 | — | — | — | |
| Loss on extinguishment of debt - related party | −333,000 | 0 | — | — | — | |
| Net change in fair value of digital assets | −62,000 | 0 | — | — | — | |
| Net change in fair value of trading marketable securities | 0 | 282,000 | 641,000 | — | — | |
| Total other (expense) income | −1 | 282,000 | 641,000 | 204,000 | 10,000 | |
| Provision for income taxes | 0 | 0 | 0 | 0 | 0 | |
| NET LOSS | −13 | −10 | −9 | −10 | −9 | |
| Foreign currency translation adjustments | −70,000 | 1,000 | 51,000 | −212,000 | −54,000 | |
| Total Other Comprehensive Income (Loss) | −70,000 | 1,000 | 51,000 | — | — | |
| TOTAL COMPREHENSIVE LOSS | −13 | −10 | −9 | −10 | −9 | |
| Basic and Diluted Loss per Common Share | −12.52 | −18.3 | −3.14 | — | — | |
| Basic and Diluted Weighted Average Common Shares Outstanding | 1 | 537,000 | 3 | — | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 600,000 | 2 | 3 | 7 | 12 | |
| Prepaid expenses and other current assets | 95,000 | 219,000 | 554,000 | 789,000 | — | |
| Total Current Assets | 695,000 | 3 | 11 | 18 | 25 | |
| Operating lease right-of-use assets | 64,000 | 99,000 | 21,000 | 60,000 | 81,000 | |
| Intangible asset | 2 | 2 | 2 | 2 | 2 | |
| Other assets | 3,000 | 3,000 | 3,000 | 3,000 | — | |
| TOTAL ASSETS | 3 | 5 | 13 | 20 | 28 | |
| Accounts payable and accrued liabilities | 3 | 2 | 1 | 905,000 | 975,000 | |
| Due to related parties | 345,000 | 61,000 | 30,000 | — | — | |
| Operating lease liabilities - current portion | 40,000 | 35,000 | 23,000 | 40,000 | 31,000 | |
| Accrued interest - convertible notes | 11,000 | 0 | — | — | — | |
| Accrued interest - convertible notes - related party | 4,000 | 0 | — | — | — | |
| Convertible notes | 437,000 | 0 | — | — | — | |
| Convertible notes - related party | 172,000 | 0 | — | — | — | |
| Total Current Liabilities | 4 | 2 | 1 | 998,000 | 1 | |
| Operating lease liabilities | 29,000 | 69,000 | 0 | 23,000 | 57,000 | |
| TOTAL LIABILITIES | 4 | 2 | 1 | 1 | 1 | |
| Preferred Stock, par value $0.001, 69,444 shares authorized, 0 shares issued and outstanding as of December 31, 2025, and 2024 | 0 | 0 | 0 | 0 | 0 | |
| Common Stock, par value $0.001, 500,000,000 shares authorized and 2,018,746 and 567,582 shares issued and outstanding as of December 31, 2025, and 2024, respectively | 2,000 | 1,000 | 3,000 | 3,000 | 3,000 | |
| Additional paid-in capital | 62 | 53 | 52 | 51 | 48 | |
| Accumulated deficit | −63 | −50 | −40 | −31 | −21 | |
| Accumulated other comprehensive loss | −272,000 | −202,000 | −203,000 | −254,000 | −18,000 | |
| TOTAL STOCKHOLDERS' (DEFICIT) EQUITY | −1 | 3 | 12 | 19 | 27 | |
| TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY | 3 | 5 | 13 | 20 | 28 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-08-31 |
|---|---|---|---|---|---|---|
| Net loss | −13 | −10 | — | — | — | |
| Net change in fair value of digital assets | 62,000 | 0 | — | — | — | |
| Non-cash lease expense | 35,000 | 33,000 | 40,000 | 39,000 | 7,000 | |
| Loss on extinguishment of debt | 825,000 | 0 | — | — | — | |
| Amortization of debt discounts and debt issuance costs | 146,000 | 0 | — | — | — | |
| Amortization of debt discounts and debt issuance costs - related party | 62,000 | 0 | — | — | — | |
| Prepaid expenses and other current assets | 129,000 | 457,000 | 430,000 | −195,000 | −239,000 | |
| Accounts payable and accrued liabilities | 1 | 449,000 | 296,000 | −10,000 | −3,000 | |
| Accounts payable - related parties | 283,000 | 31,000 | −23,000 | 33,000 | 0 | |
| Accrued interest | 48,000 | 0 | — | — | — | |
| Accrued interest - related party | 21,000 | 0 | — | — | — | |
| Fixed cash payments related to operating leases | −35,000 | −30,000 | −40,000 | −43,000 | −2,000 | |
| Net cash used in operating activities | −9 | −8 | −8 | −8 | −6 | |
| Purchase of digital assets | −250,000 | 0 | — | — | — | |
| Proceeds from disposition of digital assets | 188,000 | 0 | — | — | — | |
| Investment in trading marketable securities | 0 | −481,000 | −14 | −13 | −6 | |
| Proceeds from disposition of marketable securities | 0 | 8 | 16 | 16 | 3 | |
| Net cash (used in) provided by investing activities | −62,000 | 8 | 4 | 3 | −3 | |
| Proceeds from issuance of common shares for cash, net | 6 | 112,000 | 567,000 | 0 | 8 | |
| Proceeds from issuance of convertible notes, net | 419,000 | 0 | — | — | — | |
| Proceeds from issuance of convertible notes, net - related party | 189,000 | 0 | — | — | — | |
| Proceeds from exercise of warrants | 132,000 | 0 | — | 0 | 6 | |
| Repayment of convertible note | −24,000 | 0 | — | — | — | |
| Net cash provided by financing activities | 7 | 112,000 | 567,000 | 0 | 14 | |
| Effect of exchange rate changes on cash | −23,000 | −8,000 | 60,000 | −224,000 | −45,000 | |
| Net change in cash and cash equivalents | −2 | −477,000 | −4 | −5 | 4 | |
| Cash paid for interest | 0 | 0 | 0 | 0 | 0 | |
| Cash paid for income taxes | 0 | 0 | 0 | 0 | 0 | |
| Initial recognition of the right-of-use asset and lease liability | 0 | 111,000 | 0 | 20,000 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is ARTELO BIOSCIENCES, INC.'s CIK number?
ARTELO BIOSCIENCES, INC.'s SEC CIK number is 0001621221 (1621221). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find ARTELO BIOSCIENCES, INC.'s SEC filings?
All of ARTELO BIOSCIENCES, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did ARTELO BIOSCIENCES, INC. last report earnings?
ARTELO BIOSCIENCES, INC. (ARTL) most recently filed an earnings 8-K with the SEC on Mar 17, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001640334-26-000461). This is ARTELO BIOSCIENCES, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is ARTELO BIOSCIENCES, INC.'s most recent earnings 8-K?
ARTELO BIOSCIENCES, INC.'s latest earnings 8-K (Item 2.02) was filed Mar 17, 2026 under accession 0001640334-26-000461. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View ARTELO BIOSCIENCES, INC.'s latest earnings 8-K →
Look up any company's CIK number →